Welcome to our dedicated page for Inari Medical news (Ticker: NARI), a resource for investors and traders seeking the latest updates and insights on Inari Medical stock.
Inari Medical, Inc. (NASDAQ: NARI) is a pioneering developer of minimally invasive devices for treating venous thromboembolism and related vascular conditions. This page provides investors and healthcare professionals with essential updates on corporate developments, financial performance, and clinical advancements.
Access real-time announcements including quarterly earnings reports, FDA clearances, clinical trial data, and strategic partnerships. Our curated news feed ensures you stay informed about NARI's innovative thrombectomy technologies and market positioning within the interventional medical device sector.
Key updates include product launch details, regulatory milestones, peer-reviewed study publications, and executive leadership changes. All content is sourced directly from verified company communications and SEC filings to ensure accuracy.
Bookmark this page for streamlined access to Inari Medical's latest developments. For comprehensive analysis of how these updates may impact long-term growth strategies, consult your financial advisor.
Inari Medical (NASDAQ: NARI) announced that data from the PEERLESS trial will be presented at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium on October 29th. The trial is a prospective, randomized controlled study comparing outcomes of patients with intermediate-risk pulmonary embolism treated with Inari's FlowTriever system versus catheter-directed thrombolysis.
The primary endpoint is a win-ratio analysis of clinical and hospital resource utilization outcomes. Dr. Wissam Jaber from Emory University School of Medicine will present the findings during the Late-Breaking Clinical Trial Sessions. This study aims to provide critical information on optimal treatment for PE patients and is the first of several RCTs Inari is conducting in the VTE space.
Inari Medical (NASDAQ: NARI), a medical device company focused on treating venous and other diseases, has announced its participation in two upcoming investor conferences. The company's management team will present at:
1. The 22nd Annual Morgan Stanley Global Healthcare Conference on Wednesday, September 4, 2024, at 7:45 a.m. Eastern Time.
2. The 2024 Wells Fargo Healthcare Conference on Friday, September 6, 2024, at 8:00 a.m. Eastern Time.
Investors and interested parties can access live audio webcasts and replays of both presentations through the 'Investor Relations' section of Inari Medical's website at https://www.inarimedical.com/.
Inari Medical (NASDAQ: NARI) has announced a succession plan for its Chief Financial Officer position. Mitch Hill, the current CFO, will retire effective October 1, 2024, after serving in the role since 2019. He will be succeeded by Kevin Strange, who is currently the SVP of Finance, Accounting, Strategy and Business Development at Inari.
Strange joined Inari in 2020 and has been leading the company's day-to-day financial and accounting operations since 2023. He brings over 15 years of experience in financial and business development leadership roles within the medical device industry. CEO Drew Hykes expressed confidence in Strange's ability to lead Inari's finance and accounting organization into its next growth phase.
Inari Medical (NASDAQ: NARI) reported strong Q2 2024 financial results, with revenue reaching $145.8 million, up 22.5% year-over-year. The company launched VenaCore, a new device for acute and chronic DVT treatment. Despite revenue growth, Inari posted a GAAP operating loss of $22.4 million and a net loss of $31.3 million. Gross margin decreased to 86.3% from 88.4% in Q2 2023. The company raised its full-year 2024 revenue guidance to $594.5-$604.5 million, projecting 20.5-22.5% growth over 2023. Inari expects to reach sustained operating profitability in the first half of 2025.
Inari Medical (NASDAQ: NARI), a medical device company focused on treating venous and other diseases, has announced it will release its second quarter 2024 financial results on Tuesday, July 30, 2024. The company will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day to discuss the results and recent highlights.
Interested parties can access the live call by dialing 844-825-9789 (domestic) or 412-317-5180 (international). The webinar can be accessed through Inari's investor relations website or by registering online. A replay of the webinar will be available shortly after the call and archived on Inari's website.
Inari Medical (NASDAQ: NARI) has filed a patent infringement lawsuit against Imperative Care and Truvic Medical. The lawsuit, lodged in the United States District Court for the Northern District of California, alleges that Truvic is infringing on eight Inari patents related to aspiration-based thrombectomy devices used for treating pulmonary emboli and deep vein thrombosis. Inari seeks injunctive relief and damages. CEO Drew Hykes emphasized the company's commitment to protecting its intellectual property rights, which are vital to its mission of improving patients' lives through innovative medical solutions.
Inari Medical, Inc. will be participating in the 2024 Bank of America Securities Healthcare Conference to present their medical device solutions for venous and other diseases. The presentation will take place on May 15, 2024, at 11:20 AM Pacific Time, with a live webcast available on their website for 30 days.
Inari Medical, Inc. reported a strong first quarter with revenue of $143.2 million, up 23.3% year-over-year. Despite a GAAP operating loss of $17.2 million, non-GAAP operating loss improved to $5.6 million. The company continues to focus on growth, driving adoption of its toolkits and investing in clinical data. Gross margin was 86.8%, and operating expenses increased due to personnel-related expenses. Inari expects full-year 2024 revenue of $592.5-602.5 million and aims for sustained operating profitability in the first half of 2025.
FAQ
What is the current stock price of Inari Medical (NARI)?
What is the market cap of Inari Medical (NARI)?
